Coegin Pharma AB
Coegin Pharma AB, a biotechnology company, engages in developing peptide-based products for hair growth and skin pigmentation in Sweden. The company develops Follicopeptide, a peptide designed to enhance hair growth; and NPP-4, a natural pigmentation peptide 4 works by facilitating the transport of melanin to the skin, mimicking the natural process that occurs during sun exposure or tanning beds.… Read more
Coegin Pharma AB (7Z6) - Net Assets
Latest net assets as of September 2025: €11.65 Million EUR
Based on the latest financial reports, Coegin Pharma AB (7Z6) has net assets worth €11.65 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€13.89 Million) and total liabilities (€2.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €11.65 Million |
| % of Total Assets | 83.86% |
| Annual Growth Rate | 7.96% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 147.11 |
Coegin Pharma AB - Net Assets Trend (2021–2024)
This chart illustrates how Coegin Pharma AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Coegin Pharma AB (2021–2024)
The table below shows the annual net assets of Coegin Pharma AB from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €25.26 Million | +274.10% |
| 2023-12-31 | €6.75 Million | -67.87% |
| 2022-12-31 | €21.01 Million | +4.69% |
| 2021-12-31 | €20.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Coegin Pharma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7377400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €25.26 Million | 100.00% |
| Total Equity | €25.26 Million | 100.00% |
Coegin Pharma AB Competitors by Market Cap
The table below lists competitors of Coegin Pharma AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Canada Silver Cobalt Works Inc
OTCQB:CCWOF
|
$6.00 Million |
|
Polygiene AB
ST:POLYG
|
$6.01 Million |
|
General Commercial & Industrial S.A
AT:GEBKA
|
$6.01 Million |
|
Canasil Resources Inc.
V:CLZ
|
$6.01 Million |
|
Snack Empire Holdings Limited
PINK:SNEHF
|
$6.00 Million |
|
Anvi Global Holdings, Inc.
OTCQB:ANVI
|
$6.00 Million |
|
SMI
BC:SMI
|
$6.00 Million |
|
Grand House Mulia Pt
JK:HOMI
|
$5.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Coegin Pharma AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,752,000 to 25,259,000, a change of 18,507,000 (274.1%).
- Net loss of 23,781,000 reduced equity.
- New share issuances of 45,029,000 increased equity.
- Other factors decreased equity by 2,741,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-23.78 Million | -94.15% |
| Share Issuances | €45.03 Million | +178.27% |
| Other Changes | €-2.74 Million | -10.85% |
| Total Change | €- | 274.10% |
Book Value vs Market Value Analysis
This analysis compares Coegin Pharma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.33x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 10.32x to 0.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.03 | €0.34 | x |
| 2022-12-31 | €0.03 | €0.34 | x |
| 2023-12-31 | €0.72 | €0.34 | x |
| 2024-12-31 | €1.02 | €0.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Coegin Pharma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -94.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-94.15%) is above the historical average (-202.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -135.24% | 0.00% | 0.00x | 1.51x | €-29.15 Million |
| 2022 | -167.69% | 0.00% | 0.00x | 1.39x | €-37.34 Million |
| 2023 | -414.38% | 0.00% | 0.00x | 2.29x | €-28.65 Million |
| 2024 | -94.15% | 0.00% | 0.00x | 1.07x | €-26.31 Million |
Industry Comparison
This section compares Coegin Pharma AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Coegin Pharma AB (7Z6) | €11.65 Million | -135.24% | 0.19x | $6.00 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |